• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.700 -0.060 (-0.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
January 09, 2026
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
November 12, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
November 07, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
October 16, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
August 28, 2025
From Kezar Life Sciences
Via Business Wire
News headline image
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 13, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
July 15, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 25, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
February 18, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
November 05, 2024
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
October 28, 2024
From Kezar Life Sciences
Via Business Wire
News headline image
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
October 17, 2024
From Kezar Life Sciences
Via Business Wire
News headline image
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
October 10, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
October 04, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
September 30, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 10, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 07, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 08, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 14, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 08, 2024
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap